Kissei’s YSELTY Gains European Approval for Endometriosis

Kissei Pharmaceutical Co (JP:4547) has released an update.

Kissei Pharmaceutical Co. has announced that its GnRH antagonist YSELTY, developed for treating endometriosis, has been approved for this additional indication by the European Commission. This approval, which follows a positive opinion from the Committee for Medicinal Products for Human Use, allows YSELTY to expand its market presence in Europe. Despite this development, the company’s financial forecast for the fiscal year remains largely unchanged.

For further insights into JP:4547 stock, check out TipRanks’ Stock Analysis page.